240 related articles for article (PubMed ID: 9603399)
1. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation.
Foley R; Couban S; Walker I; Greene K; Chen CS; Messner H; Gauldie J
Bone Marrow Transplant; 1998 Apr; 21(8):769-73. PubMed ID: 9603399
[TBL] [Abstract][Full Text] [Related]
2. Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation.
Remberger M; Ringdén O
Transplantation; 1995 Dec; 60(11):1293-9. PubMed ID: 8525524
[TBL] [Abstract][Full Text] [Related]
3. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease.
Miyamoto T; Akashi K; Hayashi S; Gondo H; Murakawa M; Tanimoto K; Harada M; Niho Y
Bone Marrow Transplant; 1996 Feb; 17(2):185-90. PubMed ID: 8640164
[TBL] [Abstract][Full Text] [Related]
4. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A
Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290
[TBL] [Abstract][Full Text] [Related]
5. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
6. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD.
Grimm J; Zeller W; Zander AR
Bone Marrow Transplant; 1998 Jan; 21(1):29-32. PubMed ID: 9486491
[TBL] [Abstract][Full Text] [Related]
7. Soluble interleukin 2 receptor (sIL-2R) levels in renal transplant recipients.
Mehta R; Shah G; Adler W; Kittur D
Clin Transplant; 2004; 18 Suppl 12():67-71. PubMed ID: 15217411
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease.
Kobayashi S; Imamura M; Hashino S; Tanaka J; Asaka M
Leuk Lymphoma; 1997 Dec; 28(1-2):159-69. PubMed ID: 9498715
[TBL] [Abstract][Full Text] [Related]
9. Soluble interleukin-2 receptor levels in cytomegalovirus disease and graft versus host disease after T-lymphocyte depleted bone marrow transplantation for hematological neoplasias.
Engelhard D; Nagler A; Singer R; Barak V
Leuk Lymphoma; 1994 Jan; 12(3-4):273-80. PubMed ID: 8167558
[TBL] [Abstract][Full Text] [Related]
10. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
[TBL] [Abstract][Full Text] [Related]
11. A multicenter study to evaluate a novel assay for quantitation of soluble interleukin 2 receptor in renal transplant recipients.
Schroeder TJ; Helling T; McKenna RM; Rush D; Jeffrey JR; Brewer B; Martin LA; Traylor D; Fisher RA; First MR
Transplantation; 1992 Jan; 53(1):34-40. PubMed ID: 1733082
[TBL] [Abstract][Full Text] [Related]
12. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.
Herbelin C; Stephan JL; Donadieu J; Le Deist F; Racadot E; Wijdenes J; Fischer A
Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909
[TBL] [Abstract][Full Text] [Related]
13. Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia.
Moon Y; Kim Y; Kim M; Lim J; Kang CS; Kim WI; Shim SI; Chung NG; Park YH; Min WS; Han K
Ann Clin Lab Sci; 2004; 34(4):410-5. PubMed ID: 15648782
[TBL] [Abstract][Full Text] [Related]
14. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation.
Ferrà C; de Sanjosé S; Gallardo D; Berlanga JJ; Rueda F; Marìn D; de la Banda E; Ancìn I; Peris J; Garcìa J; Grañena A
Haematologica; 1998 Dec; 83(12):1082-7. PubMed ID: 9949625
[TBL] [Abstract][Full Text] [Related]
15. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of serum cytokines after allogeneic bone marrow transplantation: interleukin-5 as a potential marker of acute graft-versus-host disease.
Imoto S; Oomoto Y; Murata K; Das H; Murayama T; Kajimoto K; Sugimoto T; Gomyo H; Nakagawa T; Nishimura R; Koizumi T
Int J Hematol; 2000 Jul; 72(1):92-7. PubMed ID: 10979216
[TBL] [Abstract][Full Text] [Related]
17. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants.
Al-Kasim FA; Thornley I; Rolland M; Lau W; Tsang R; Freedman MH; Saunders EF; Calderwood S; Doyle JJ
Br J Haematol; 2002 Feb; 116(2):483-90. PubMed ID: 11841456
[TBL] [Abstract][Full Text] [Related]
18. High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation.
MacMillan ML; Radloff GA; Kiffmeyer WR; DeFor TE; Weisdorf DJ; Davies SM
Transplantation; 2003 Dec; 76(12):1758-62. PubMed ID: 14688528
[TBL] [Abstract][Full Text] [Related]
19. Soluble interleukin 2 receptors in patients after bone marrow transplantation.
Siegert W; Josimovic-Alasevic O; Schwerdtfeger R; Baurmann H; Schmidt CA; Musch R; Schmid HJ; Hartmann R; Henze G; Huhn D
Bone Marrow Transplant; 1990 Aug; 6(2):97-101. PubMed ID: 2207458
[TBL] [Abstract][Full Text] [Related]
20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]